EGFR and non-small cell lung carcinoma: In addition, the mPFS of treatment with SFI combined with first-generation EGFR-TKIs was significantly better than the mPFS of first-generation EGFR-TKIs (gefitinib: 9.6 months; erlotinib: 13.3 months; icotinib: 11.2 months) in series of phase III clinical trials results (Kelly et al. 2019; Saito et al. 2019; Shi et al. 2017), suggesting that this combination regimen are capable of effectively controlling tumor progression in advanced NSCLC patients harboring EGFR-sensitive mutations, producing significantly longer PFS, and slowing down the onset of drug resistance.